Weekly FDA Roundup: April 25 to May 1, 2026

The most consequential FDA action of the week was a proposal that, if finalized, would functionally end large-scale compounding of the three best-selling GLP-1s the moment shortages clear. The week also surfaced a brutal pattern in diabetes care: two Class I recalls, one with a confirmed death, the other with more than 470 reported injuries. And a 22-year-old depression drug just became the first non-antipsychotic ever approved for dementia agitation. Six things our subscribers should not miss, plus a compliance calendar at the end.

1. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list

On April 30, FDA proposed to exclude all three blockbuster GLP-1 receptor agonists from the list of bulk drug substances that outsourcing facilities can use under section 503B. The agency's stated reason: there is no clinical need for compounded versions of these drugs from bulk substances when FDA-approved versions are available. The Federal Register notice posted May 1; comments are due June 29, 2026 (Docket No. FDA-2018-N-3240).

Why this matters. Outsourcing facilities have been the only legal compounding pathway left for semaglutide, tirzepatide, and liraglutide once each drug came off the FDA shortage list (semaglutide: November 2024; tirzepatide: October 2024; liraglutide: never on shortage). 503A pharmacies were already largely walled off. This proposal is the second, larger door closing.

What we recommend. If your business model touches compounded GLP-1s, file a comment by June 29 with specific clinical-need evidence, or pivot now. The agency's tone signals this is not a close call. Watch for litigation from compounder trade groups. The Outsourcing Facilities Association already sued FDA over the 2024 tirzepatide shortage delisting, won a brief remand, and saw the agency reaffirm the delisting on reevaluation. A similar outcome would not change the trajectory here.

Source: FDA press announcement, April 30 | Federal Register notice, May 1

2. Two Class I recalls in diabetes care, in the same 24 hours

This was the worst week for diabetes device safety in recent memory.

Trividia Health TRUE METRIX blood glucose monitoring systems (Class I, posted April 28). The meters display the same E-5 error code for two completely different conditions: a critically high glucose reading above 600 mg/dL, and a test strip error. Patients reading the screen cannot tell the difference. As of January 16, Trividia reported 114 serious injuries and one death linked to the ambiguous code. FDA is not requiring product return; the correction is to the labeling and the user instructions only.

Insulet Omnipod 5 Pods (Class I, posted April 29). Internal tubing in certain pod lots can tear. Insulin then leaks inside the pod instead of reaching the patient. Result: significant insulin under-delivery, hyperglycemia, and risk of diabetic ketoacidosis. More than 470 serious injuries reported. Affected lots are listed in the recall notice.

What we recommend. If you sell, distribute, or clinically advise on either device, push the corrective communication to your downstream channel today, not next week. For Trividia, the patient-facing risk is interpretive. Providers need to retrain patients on what an E-5 code actually means and to escalate any high-glucose symptoms regardless of error code. For Insulet, identify and quarantine affected lots immediately.

Sources: Trividia recall | FDA Safety Communication, Trividia | Insulet Omnipod 5 recall

3. Bolton Medical thoracic stent graft early alert: three deaths

CDRH issued an early alert on April 28 for the Bolton Medical (Terumo Aortic) Relay Pro Thoracic Stent Graft System, non-bare stent configuration, 32 mm and above. Mechanical failure mode: the stent graft cannot be released from the delivery system once deployment begins. The defect cannot be identified before use. Three patient deaths have been associated with the failure to date. FDA's recommendation to clinicians is to consider alternative stent grafts and to review existing bailout methods in the IFU.

What we recommend. Hospital purchasing and cardiothoracic departments should pause new ordering of the affected configurations and confirm bailout plans with on-call surgical teams. This is the kind of alert that drives rapid market share shifts in vascular devices; competitors with comparable thoracic platforms should expect inbound demand.

Source: Early Alert: Thoracic Stent Graft Issue from Bolton Medical

4. Auvelity becomes the first non-antipsychotic approved for dementia agitation

On April 30, FDA approved Axsome Therapeutics' Auvelity (dextromethorphan HBr / bupropion HCl, extended-release) for agitation associated with Alzheimer's dementia in adults. This is the second drug ever approved for the indication (the first was Otsuka's Rexulti, an atypical antipsychotic, in 2023) and the first that is not an antipsychotic. The supplemental NDA was supported by four randomized, double-blind trials and received Breakthrough Therapy and Priority Review designations. The label retains a Boxed Warning for suicidal thoughts and behaviors in younger patients and requires monitoring for seizures and hypertension.

Why this matters. Antipsychotics carry a Boxed Warning for increased mortality in elderly dementia patients. A non-antipsychotic option changes the prescribing calculus in long-term care and home-care settings, where roughly half of dementia patients experience clinically significant agitation.

Source: FDA press announcement

5. Real-time clinical trials get a pilot program

FDA announced on April 28 that it is moving toward "real-time" clinical trials, with proof-of-concept work already underway with AstraZeneca and Amgen. The agency issued a Request for Information for a broader pilot launching in summer 2026. The premise: AI and modern data infrastructure let FDA scientists view safety signals and trial endpoints continuously, potentially eliminating the months-long pause between phases.

If sponsors can adapt to continuous review, drug development timelines could compress materially. The constraint is not the technology, it is sponsor and IRB readiness for continuous data sharing. RFI comments are due May 29 (Docket No. FDA-2026-N-4390).

Source: FDA Announces Major Steps to Implement Real-Time Clinical Trials

6. Largest-ever infant formula testing program: results in, action levels coming

Also on April 29, FDA released results from the largest surveillance study of chemical contaminants in U.S. infant formula on record. The agency tested for heavy metals, pesticides, PFAS, and phthalates. Headline finding: the supply is generally safe under current standards. Headline subtext: FDA will now move to set formal action levels for those contaminants under the Closer to Zero initiative, and will convene industry to "modernize oversight," a phrase that historically precedes specific limits and tightened recall criteria.

Formula manufacturers should expect proposed action levels within 12 months and should not wait for the comment period to begin contaminant baselining. The agency is signaling the direction; the question is the threshold.

Source: FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.

Quick hits

• TAVNEOS proposed withdrawal. FDA proposed to withdraw approval of ChemoCentryx's TAVNEOS (avacopan) 10 mg capsules and gave the manufacturer the opportunity for a hearing. Comment deadline: June 29 (Docket FDA-2026-N-1321).
• Class II 510(k) exemption RFI. FDA is asking for comments on which Class II devices no longer need premarket notification to assure safety and effectiveness. Comments due June 30 (Docket FDA-2026-N-4268). This is a meaningful deregulatory signal for device manufacturers.
• Three CGMP warning letters in one week. Intas Pharmaceuticals (Dehradun, India): data integrity in electronic batch records and unresolved out-of-specification investigations. Lexia LLC: finished pharmaceuticals with no laboratory testing, no stability, no quality unit; firm has ceased manufacturing. Foshan Miwei Cosmetics: OTC sunscreens marketed with non-monograph ingredients, placed on Import Alert 66-40.
• Two food enforcement actions. Nupack Inc.: dietary supplements marketed with disease claims (Diabetech, Cardiag, MACA), CGMP violations under 21 CFR Part 111. The Wilatta Group: failure to develop a Foreign Supplier Verification Program for imported melon seeds, condensed milk powder, and chocolate spread; warned of placement on DWPE under Import Alert 99-41.
• B. Braun Lactated Ringer's recall. Voluntary nationwide recall of two lots (J4P756, J4S843) of 1L Lactated Ringer's Injection due to particulate matter (cellulose, stearates, trace copper). Hospital pharmacy should verify lot numbers in active stock.
• Pancreatic cancer expanded access. FDA cleared Revolution Medicines' RAS inhibitor daraxonrasib (RMC-6236) for an expanded access protocol in metastatic pancreatic ductal adenocarcinoma.

Compliance deadlines for the next 60 days

Date	Item	Docket
May 29, 2026	RFI: AI-Enabled Optimization of Early-Phase Clinical Trials	FDA-2026-N-4390
June 1, 2026	Comment: Juice HACCP information collection	FDA-2026-N-0499
June 29, 2026	Comment: 503B bulks list (GLP-1 exclusion)	FDA-2018-N-3240
June 29, 2026	Comment: TAVNEOS proposed withdrawal	FDA-2026-N-1321
June 29, 2026	Comment: Good Laboratory Practice information collection	FDA-2026-N-3532
June 30, 2026	Comment: PFDD meetings impact docket	FDA-2026-N-3947
June 30, 2026	Comment: Obesity drug dosing clinical pharmacology	FDA-2026-N-3499
June 30, 2026	Comment: Class II 510(k) exemption candidates	FDA-2026-N-4268

Pattern we are watching

Two themes anchored this week. First, the GLP-1 enforcement arc is moving from individual warning letters (we covered the 30-letter day in March) to structural exclusion at the bulks-list level. The compounding window for these molecules is closing through policy itself, no longer through enforcement alone. Second, glucose-management devices had a uniquely bad week: one death, more than 580 combined injuries across two Class I actions in 24 hours. Both stories will compound with the GLP-1 story over time. As compounded GLP-1s exit the market and prescribers shift to branded therapy, more patients will rely on the devices, and the safety floor under those devices needs to be higher than what we saw this week.

---

Drafted by Policy Canary. Sources are FDA primary documents and Federal Register notices, with secondary verification via web search where noted. Subscribers receive personalized alerts for the substances and product categories they monitor.